Summary
The antiarrhythmic activity of intravenous moxaprindine was evaluated in 26 patients with cardiovascular disease; the mean maximum dose was 2.5±0.12 mg/kg. Ventricular extopics were completely abolished in 19 patients and significantly reduced in four patients, but were not favourably affected in three patients. In one patient with numerous runs of ventricular tachycardia, normal sinus rhythm was restored. Coupled ventricular ectopic activity always completely disappeared. At the maximum dose, the PR-interval (+27.7±3.3%), the QRS-duration (+24.6±2.2%), the QT-interval (+17.0±1.5%) and the QTc-interval (+10.8±1.2%) were significantly prolonged. The QRS morphology essentially remained unchanged. Moxaprindine caused first degree atrioventricular block in eight patients. The sinus rate was slowed at every dosage level. Nevertheless, moxaprindine could safely be administered to patients with dysfunction of the specialized conduction system, or with a damaged myocardium. Serious side effects did not occur. Moxaprindine is a promising new antiarrhytmic drug for the treatment of ventricular arrhythmias, but its value and safety in the chronic oral treatment of these arrhythmias remain to be established.
Similar content being viewed by others
References
Baedeker W, Rastetter J (1977) Agranulozytose nach Aprindine-Behandlung. Münch Med Wochenschr 119: 1047–1048
Collard E, Lambert M, Delespesse G, Stryckmans P (1981) Comparison of the inhibitory effects of two anti-arrhythmic drugs (aprindine and moxaprindine) on hematopoietic cells in culture. Submitted for publication
Carmeliet E, Verdonck F (1974) Effects of aprindine and lidocaine on transmembrane potentials of K-efflux in different cardiac tissues. Acta Cardiol (Brux) (Suppl) 8: 73–90
Danilo P (1979) Aprindine. Am Heart J 97: 119–124
Friedman, H (1971) Diagnostic electrocardiography and vectorcardiography. McGraw-Hill, London New York, p 77
Kesteloot H, Van Mieghem W, De Geest H (1973) Aprindine, a new anti-arrhythmic drug. Acta Cardiol (Brux) 28: 145–165
Kesteloot H (1977) Recent advances in the pharmacological treatment of rhythm disturbances. Tijdschr Geneeskd 17: 941–944
Kesteloot H, Van de Werf F, Marchandise B, Sluyts R (1979) Influence of moxaprindine treatment on ventricular arrhythmias occurring during maximum exercise stress testing. Acta Cardiol (Brux) 34: 301–309
Reid PR, Grune HL, Varghese PJ (1977) Suppression of refractory arrhythmias by aprindine in patients with the Wolff-Parkinson-White syndrome. Br Heart J 39: 1353–1360
Troup PJ, Zipes DP (1979) Aprindine treatment of recurrent ventricular tachycardia in patients with mitral valve prolapse. Am Heart J 97: 322–328
Van Leeuwen R, Meyboom RB (1976) Agranulocytosis and aprindine. Lancet 2: 1137
Waleffe A, Mary-Rabine L, Kulbertus HE (1980) Study of moxaprindine with programmed electric stimulation of the heart in patients with reentrant tachyarrhythmias. Am J Cardiol 45: 640–647
Wei JY, Bulkley BH, Schaeffer, AH, Greene HL, Reid PR (1978) Mitral valve prolapse syndrome and recurrent ventricular tachyarrhythmias. A malignant variant refractory to conventional drug therapy. Ann Intern Med 89: 6–9
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Staessen, J., Kesteloot, H. Moxaprindine in the acute treatment of ventricular arrhythmias in patients with cardiovascular disease. Eur J Clin Pharmacol 19, 167–172 (1981). https://doi.org/10.1007/BF00561943
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561943